Ocuphire Pharma
primary of subjects study eye returned to at min | Ocuphire Pharma
Company
Deck Type
Deck date
March 2022
Slide
17 of 38
Similar slides by Ocuphire Pharma
See diffirences between slides (animation)
Results
March 2022
mean pupil diameter over time by eye color | Ocuphire Pharma
Results
March 2022
mean pupil diameter over time by mydriatic agents | Ocuphire Pharma
Results
March 2022
mean pupil diameter over time | Ocuphire Pharma
Results
March 2022
comparison of one drop fellow eye with two drops study eye | Ocuphire Pharma
Related slides by other companies
NeuroSense Therapeutics
Investor Presentation
December 2023
phase study results achieved primary with a safety and tolerability profile comparable to placebo | NeuroSense Therapeutics
Oculis
Results
August 2023
consistent results with in optimize trials | Oculis
ATAI
Investor Presentation
March 2023
dose low doses enhanced learning and memory verbal learning delayed recall dose phase exploratory patients additionally a third party study in of also showed statistically significant positive cognitive signals | ATAI
GH Research
Investor Presentation
March 2023
phase efficacy | GH Research
Other recent decks by Ocuphire Pharma
See all presentations (10 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
May 2023
Results
January 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io